$29.39
-5.01-14.58%
Last update: Nov 4, 11:01 AM

UroGen Pharma (URGN) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
| Metric | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $0.09 | $-0.31 | $-0.50 | $-0.57 |
| Actual | $-0.03 | $-0.28 | $-0.47 | $-0.54 |
| Surprise | -133.3% | +9.68% | +6.00% | +5.26% |
| Revenue | ||||
| Estimate | $89.3M | $62.1M | $44.6M | $38.2M |
| Actual | $89.0M | $72.5M | $51.0M | $37.8M |
| Surprise | -0.29% | +16.7% | +14.3% | -0.88% |
| Metric | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|
| Earnings Per Share (Non-GAAP) | |||
| Consensus | $0.40 | $0.15 | $0.26 |
| Revenue | |||
| Consensus | $107.1M | — | — |
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q3 | Nov 4, 2026 | $-0.03 | $0.09 | -133.3 % |
| Q2 | Aug 5, 2026 | $-0.28 | $-0.31 | 9.68 % |
| Q1 | May 6, 2026 | $-0.47 | $-0.50 | 6.00 % |
| Q4 | Mar 2, 2026 | $-0.54 | $-0.57 | 5.26 % |
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q3 | Nov 4, 2026 | $89.00M | $89.26M | -0.29 % |
| Q2 | Aug 5, 2026 | $72.46M | $62.10M | 16.7 % |
| Q1 | May 6, 2026 | $50.96M | $44.57M | 14.3 % |
| Q4 | Mar 2, 2026 | $37.84M | $38.17M | -0.88 % |